DocMorris AG (ZRSEF)
USD 39.03
(0.0%)
USD 39.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -56.08 Million CHF | 43.02% |
| 2022 | -111.94 Million CHF | 33.36% |
| 2021 | -159.35 Million CHF | -101.22% |
| 2020 | -79.22 Million CHF | -152.58% |
| 2019 | -31.35 Million CHF | -90.73% |
| 2018 | -17.98 Million CHF | -59.03% |
| 2017 | -17.09 Million CHF | -1555.77% |
| 2016 | -1.02 Million CHF | -94.38% |
| 2015 | 13.87 Million CHF | -21.16% |
| 2014 | 16.01 Million CHF | 963.61% |
| 2013 | -4.01 Million CHF | 138.26% |
| 2012 | 12.01 Million CHF | -139.61% |
| 2011 | 9.93 Million CHF | -23.93% |
| 2010 | 12.89 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -10.82 Million CHF | 0.0% |
| 2024 Q1 | -10.82 Million CHF | -5.78% |
| 2023 Q3 | -10.08 Million CHF | 64.14% |
| 2023 Q2 | -28.13 Million CHF | -100.0% |
| 2023 FY | - CHF | 43.02% |
| 2023 Q1 | -14.06 Million CHF | 59.32% |
| 2023 Q4 | -10.23 Million CHF | -1.45% |
| 2022 Q3 | -27.81 Million CHF | 35.44% |
| 2022 FY | - CHF | 33.36% |
| 2022 Q1 | -32.3 Million CHF | 65.23% |
| 2022 Q2 | -43.07 Million CHF | -33.33% |
| 2022 Q4 | -34.58 Million CHF | -24.35% |
| 2021 Q2 | -49.71 Million CHF | -100.0% |
| 2021 FY | - CHF | -101.22% |
| 2021 Q1 | -24.85 Million CHF | 53.91% |
| 2021 Q4 | -92.92 Million CHF | -72.3% |
| 2021 Q3 | -53.92 Million CHF | -8.48% |
| 2020 Q3 | -32.14 Million CHF | -31.44% |
| 2020 FY | - CHF | -152.58% |
| 2020 Q4 | -53.92 Million CHF | -67.78% |
| 2020 Q2 | -24.45 Million CHF | -100.0% |
| 2020 Q1 | -12.22 Million CHF | -7.39% |
| 2019 FY | - CHF | -90.73% |
| 2019 Q1 | -13.32 Million CHF | -141.6% |
| 2019 Q2 | -2.45 Million CHF | 81.56% |
| 2019 Q4 | -11.38 Million CHF | -9.64% |
| 2019 Q3 | -10.38 Million CHF | -322.84% |
| 2018 Q2 | -4.48 Million CHF | 0.0% |
| 2018 FY | - CHF | -59.03% |
| 2018 Q1 | -4.48 Million CHF | 37.23% |
| 2018 Q4 | -5.51 Million CHF | -16.22% |
| 2018 Q3 | -4.74 Million CHF | -5.89% |
| 2017 Q2 | -5.84 Million CHF | 22.04% |
| 2017 Q1 | -7.49 Million CHF | -75.85% |
| 2017 FY | - CHF | -1555.77% |
| 2017 Q4 | -7.13 Million CHF | -8.44% |
| 2017 Q3 | -6.58 Million CHF | -12.63% |
| 2016 Q4 | -4.26 Million CHF | -11.86% |
| 2016 Q3 | -3.81 Million CHF | -170.78% |
| 2016 Q2 | 5.38 Million CHF | 550.77% |
| 2016 Q1 | 827.25 Thousand CHF | -42.68% |
| 2016 FY | - CHF | -94.38% |
| 2015 Q1 | 3.2 Million CHF | -45.21% |
| 2015 Q4 | 1.44 Million CHF | -0.93% |
| 2015 Q3 | 1.45 Million CHF | -54.58% |
| 2015 FY | - CHF | -21.16% |
| 2015 Q2 | 3.2 Million CHF | 0.0% |
| 2014 Q2 | 4.32 Million CHF | 0.0% |
| 2014 Q1 | 4.32 Million CHF | 265.76% |
| 2014 Q4 | 5.85 Million CHF | -2.28% |
| 2014 FY | - CHF | 963.61% |
| 2014 Q3 | 5.98 Million CHF | 38.44% |
| 2013 Q2 | 2.22 Million CHF | 0.0% |
| 2013 Q3 | -2.72 Million CHF | -222.43% |
| 2013 Q4 | -2.61 Million CHF | 4.16% |
| 2013 FY | - CHF | 138.26% |
| 2013 Q1 | 2.22 Million CHF | 0.0% |
| 2012 FY | - CHF | -139.61% |
| 2011 FY | - CHF | -23.93% |
| 2010 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | -251.11 USD | -22333538.644% |
| Allstar Health Brands, Inc. | -241.78 Thousand USD | -23094.795% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 89.4 Million USD | 162.731% |
| Café Serendipity Holdings, Inc. | -1.41 Million USD | -3862.563% |
| Decision Diagnostics Corp. | - USD | Infinity% |
| Health Advance Inc. | -47.95 Thousand USD | -116839.822% |
| HealthWarehouse.com, Inc. | -1.27 Million USD | -4297.529% |
| LIGAND PHARMACEUTICAL INC | 47.23 Million USD | 218.737% |
| MedGen, Inc. | -15.37 USD | -364879535.654% |
| Omni Health, Inc. | 1.28 Million USD | 4455.552% |
| Oxford Investments Holdings Inc. | -343.96 Thousand USD | -16204.518% |
| Pineapple, Inc. | -1.47 Million USD | -3701.453% |
| ScripsAmerica, Inc. | -3.95 Million USD | -1318.193% |